Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma-Reference-Cited by-同舟云学术

Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma

Published:2019-02-27 Issue:5 Volume:8 Page:e1577108
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Jahan Nusrat¹,Talat Hammad¹,Alonso Andrea²,Saha Dipongkor³,Curry William T.⁴

Affiliation:

1. Translational Brain Tumor Immunotherapy Laboratory, Massachusetts General Hospital, Boston, MA, USA

2. Deparment of Immunotherapeutics and Biotechnology, Case Western Reserve University School of Medicine, Cleveland, OH, USA

3. Texas Tech University Health Sciences Center School of Pharmacy, Abilene, TX, USA

4. Pappas Center for Neuro-Oncology, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2019.1577108

Reference31 articles.

1. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

2. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

3. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

4. A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

5. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy against glioblastoma using backpack‐activated neutrophils;Bioengineering & Translational Medicine;2024-08-13

2. In vivo mouse models for adult brain tumors: Exploring tumorigenesis and advancing immunotherapy development;Neuro-Oncology;2024-07-11

3. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival;Journal for ImmunoTherapy of Cancer;2024-04

4. Different concentrations of nivolumab reduce PD-1 expression but not tumour growth in an EMT6 mouse model;Biomedical Research and Therapy;2024-02-29

5. From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review;Journal of Experimental & Clinical Cancer Research;2024-02-12